Program
Sutantatug Envedotin
Also written as “SYS6002” and “CRB-701”.
Its studies are mostly in Oropharyngeal Neoplasms · Carcinoma, Transitional Cell · Uterine Cervical Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 44 open or running | phase 3since Nov 13, 2025 | Apr 25, 2025 | Dec 30, 2027phase 2 · NCT06989671 |
| Corbus Pharmaceuticals | 22 open or running | phase 3since Aug 12, 2026 | Feb 8, 2024 | Jan 16, 2027phase 2 · NCT06265727 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 8, 2024First study: phase 2 study in Solid Tumor, AdultNew to Corbus PharmaceuticalsCorbus Pharmaceuticals · NCT06265727 · 348 planned · United States, France, Italy and more
- Apr 25, 2025CSPC Pharmaceutical Group’s first study: phase 2 study in Squamous Cell Carcinoma of Head and NeckNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06989671 · 430 planned
- Nov 13, 2025Phase 3 study in Uterine Cervical NeoplasmsCSPC Pharmaceutical Group · NCT07230626 · 412 planned
- Jan 21, 2026Phase 2 study in Advanced Urothelial CarcinomaCSPC Pharmaceutical Group · NCT07374549 · 100 planned
- Apr 7, 2026Phase 3 study in Carcinoma, Transitional CellCSPC Pharmaceutical Group · NCT07526792 · 406 planned
- Aug 12, 2026Phase 3 study in Oropharyngeal NeoplasmsPhase 3 reachedCorbus Pharmaceuticals · NCT07768189 · 260 planned · United States, Austria, Belgium and more
Ahead
- Jan 16, 2027Primary completion: phase 2 study in Solid Tumor, AdultCorbus Pharmaceuticals · NCT06265727
- Dec 2027Primary completion: phase 3 study in Oropharyngeal NeoplasmsCorbus Pharmaceuticals · NCT07768189
- Dec 30, 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckCSPC Pharmaceutical Group · NCT06989671
- Jan 1, 2028Primary completion: phase 3 study in Uterine Cervical NeoplasmsCSPC Pharmaceutical Group · NCT07230626
TargetBeta
“An antibody-drug conjugate (ADC) composed of sutantatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4), site-specifically ”NCIt, by rule
Other programs on NECTIN4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enfortumab vedotinrule | Astellas Pharma | phase 4 | 20 |
| notiretatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 14 |
| bulumtatug fuvedotinrule | Mabwell (Shanghai) Bioscience | phase 3 | 13 |
| zelenectide pevedotinrule | bicycletx-limited | phase 2 | 5 |
| Anti-nectin-4 Antibody-drug Conjugate MK-3120rule | Merck | phase 2 | 5 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-nectin-4 Antibody-drug Conjugate IPH4502rule | innate-pharma | phase 1 | 1 |
| Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rule | rondo-therapeutics | phase 1 | 1 |
| CT-202rule | context-therapeutics-inc | phase 1 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07768189Oropharyngeal Neoplasms · United States, Austria, Belgium and more | 3 | Recruiting | Corbus Pharmaceuticals | Dec 2027 | 260 |
| NCT07526792Carcinoma, Transitional Cell | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 1, 2029 | 406 |
| NCT07374549Advanced Urothelial Carcinoma | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 1, 2028 | 100 |
| NCT07230626Uterine Cervical Neoplasms | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Jan 1, 2028 | 412 |
| NCT06989671Squamous Cell Carcinoma of Head and Neck | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 30, 2027 | 430 |
| NCT06265727Solid Tumor, Adult · United States, France, Italy and more | 2 | Recruiting | Corbus Pharmaceuticals | Jan 16, 2027 | 348 |
How it is read
Names in the registry
- “SYS6002”, 4 entries
- “CRB-701”, 2 entries
Conditions, from the studies’ own filings
- Oropharyngeal Neoplasms, 1 study
- Carcinoma, Transitional Cell, 1 study
- Uterine Cervical Neoplasms, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.